Balik Scientists. Balik Puso. Balik Pilipinas.
Seven Filipino virologists who were trained abroad responded to the call of the Department of Science and Technology (DOST) to be part of the first-of-its-kind Virology and Vaccine Institute of the Philippines or VIP.
As they are scheduled to pay a courtesy call on Department of Science and Technology (DOST) Secretary Fortunato Boy T. de la Pea on Friday, Aug. 13, they are expected to share their expertise in the study and development of local vaccines against the coronavirus disease (COVID-19) and their scientific researches on virology and other diseases.
It has been noted that from 1975 to 2020, the DOST was able to work with 564 Balik Scientists through 716 engagements under its brain gain flagship initiative, Balik Scientist Program (BSP).
The Balik Scientist Program has been bringing home Filipino scientists from all corners of the world for almost 46 years now, DOST Undersecretary for Research and Development Rowena Cristina L. Guevara told the Manila Bulletin.
As the Philippines continues to fight and brace itself for the effects of the pandemic, we saw the eagerness and dedication of our Balik Scientists to help our country. We wish to express our gratitude to our Balik Scientists for their unconditional and unwavering love and service to the country.
As the DOST is set to roll down its red carpet to the seven Balik Scientists, it is good to know their affiliations and expertise, putting them at the heart of the anatomy of the VIP which may rise at the New Clark Economic Zone in Capas, Tarlac by the end of 2023 or in 2024.
The profiles of the seven Filipino virologists were provided by Office of the Undersecretary for Research and Development, led by Guevara.
DR. ELPIDIO CESAR NADALA JR.
Ph.D. in Microbiology and Animal Virology
Post Doctoral in Aquatic Virology and Medical Biotechnology
-Vice President of Research and Development, Diagnostics for the Real World, Ltd (DRW), California, USA
Dr. Elpidio Cesar Nadala Jr. is a virologist and microbiologist with 20 years of experience in academic research and 17 years in the industry developing diagnostic assays for the detection of bacterial and viral pathogens.
He is the co-founder of the Diagnostics for the Real World, Ltd (DRW), where he spearheaded the development of rapid diagnostic tests for the detection of Hepatitis B Virus (HBV) surface antigen, Human Immunodeficiency Virus (HIV) antibodies, and Hepatitis C Virus (HCV) antibodies, as well as improved versions of the CE-marked Chlamydia rapid test.
His team was behind the development of the SAMBA II SARS-CoV-2 test for detection of SARS-CoV-2 RNA. The SAMBA II SARS-CoV-2 test was developed and validated within two months in 2020.
Currently, the SAMBA II SARS-CoV-2 test is used in 79 hospitals and schools in the United Kingdom with a total of 648 Assay Modules deployed and 300,000 tests used so far.
DR. LOURDES NADALA
Ph.D. in Microbiology (Major in Animal Virology)
-Vice President, Regulatory Affairs/Quality Assurance, Diagnostics for the Real World, Ltd (DRW)
Dr. Lourdes Nadala is a microbiologist/virologist by training with over 15 years of experience in microbial systematics and culture collection-related activities and over 20 years of shrimp and human diagnostics, including ISO accreditation and successful regulatory submission of in vitro diagnostic medical devices.
She spearheaded DRWs efforts for ISO 13485 accreditation and regulatory approval of in vitro diagnostic (IVD) products which include molecular point-of-care tests for early diagnosis of HIV in infants, viral load monitoring, and recently, SARS-CoV-2 Test using the SAMBA platform.
She also has extensive experience in field evaluations and clinical trials in IVDs.
She also worked on detection methods for infectious pathogens and spoilage organisms affecting food safety, ISO accreditation for 9001 and ISO Guide 34 (Reference materials), AOAC validations, and customer-driven research projects related to food safety and shelf life.
DR. TEODORO FAJARDO JR.
Ph.D. in Molecular Biology (Major in Molecular Biology and Molecular Virology
Post Doctoral Fellow at London School of Hygiene and Tropical Medicine, UK with PhD in Public Administration (Major in Public Management)
-Healthcare Scientist Team Manager , UK National External Quality Assessment Service (NEQAS)
Dr. Teodoro Fajardo Jr. has specialization in Molecular Virology and Molecular Biology (which includes but not limited to: gene cloning, virus isolation, culture, propagation, and virus plaque assay, TCID50, reverse genetics virus propagation, generating infectious RNA of (+) RNA virus creating virus progeny from in-vitro transcribed RNA, and other molecular virology techniques (in vitro RNA synthesis of full-length viral RNA, in vitro RNA transcription, cell-free and mammalian cell mRNA translation, cell-free viral assembly system, RNA-RNA interactions assay for viral RNA packaging and assembly, nucleic acid isolation and purification, site-directed mutagenesis and cloning,gel electrophoresis, viral protein isolation and analysis, western blot, in vitro and in vivo gene expression of monocistronic and bicistronic mRNA, in-vitro mRNA translation, transfection of cultured cell, viral plaque analysis, analysis of expressed viral proteins)
DR. MYRA HOSMILLO
Ph.D. in Molecular Medical Science
Post Doctoral Fellow in Professor Ian Goodfellows Lab, Division of Virology, Department of Virology
-Research Associate, Division of Virology, Department of Pathology, University of Cambridge
Dr. Myra Hosmillo is an expert in the field of virology, specifically on veterinary and medical virology with a 12-year research career largely focused on virus-causing gastroenteritis.
She first worked on animal viral gastroenteritis caused by rotaviruses, caliciviruses, hepatitis E virus, toroviruses, and coronaviruses.
She was also involved in developing experimental systems to use animal viruses as a surrogate model of human viruses; particularly established an enhanced cell culture system and reverse genetics of porcine sapovirus to study its virus replication and the interactions with host innate immune response.
In Cambridge, she developed fundamental systems to directly study the pathogenesis of human norovirus using human intestinal organoids and replicon systems in human gastric tumor cells.
DR. CHRISTINA LORA LEYSON
PhD in Infectious Diseases
-Postdoctoral Researcher, Exotic and Emerging Avian Viral Diseases Group, Southeast Poultry Research Laboratory (SEPRL)
Dr. Christina Lora Leyson is an expert in standard DNA, RNA, and protein laboratory techniques including quantitative PCR, cloning, and protein expression and knowledge on sequence analysis, phylogenetics, and homology modeling with basic coding skills using Python for applications such as data wrangling and analysis.
DR. HOMER PANTUA, DVM
Ph.D. in Biomedical Sciences specializing in Immunology and Virology
-Genentech, South San Francisco, CA, USA; BioAssets Corporation
Dr. Homer Pantua is an Innovative and motivated infectious disease drug discovery scientist with over 13 years of industry experience as the lead scientist.
He has strong technical skills that encompass microbiology, molecular biology, immunology, biochemistry, and biotechnology.
He has an excellent track record of working as a lead scientist in diverse projects that progressed from early discovery to development.
DR. LEODEVICO L. ILAG
Ph.D. in Microbiology and Immunology; Postdoctoral Research Fellow in Structural biology of viruses and viral proteins
-Molawin Creek Ventures Pty. Ltd. (Melbourne, Victoria, Australia); Xerion Ltd (Brighton, Victoria, Australia); Philippine Asian Biotechnology R&D, Inc. (Manila, Philippines); Plentex Philippines, Inc, Plentex Realty Inc, PlentexAgri-Milling Corp, Plentex Aquaculture Corp (Tacloban, Leyte, Philippines)
Dr. Leodevico L. Ilag is a veteran microbiologist and immunologist with 25 years of solid research in discovery, preclinical and clinical development of biologics and dietary/food ingredients (peptides, proteins, antibodies, natural products, agricultural waste streams) with applications in oncology, cardiovascular disease, CNS, infectious disease, metabolic disease, and dermatology.
He has technical experience in antibody engineering; structural biology; virology; immunology; biochemistry; microbiology; genetics.
He has 25 years of international (Europe, US, Asia, and Australia) entrepreneurial biotechnology experience (R&D, business development/licensing/deal-making, strategy, general management, intellectual property management, financing, and operations) from conception through seed financing to initial public offering (IPO) raising the equivalent of more than A$80 million.
SIGN UP TO DAILY NEWSLETTER
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated... - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022